GLPwatch
Mounjaro for Fertility ("Ozempic babies")
tirzepatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCMounjaro (tirzepatide) is not FDA-approved for improving fertility. Research includes studies on its effects on contraception, weight loss in women by reproductive stage, a clinical trial protocol for fertility-sparing treatment in certain patients, and a systematic review of broader therapeutic benefits.
AI summary of the sources below.
| Drug | Mounjaro (tirzepatide) |
|---|---|
| Condition | Fertility ("Ozempic babies") |
| Approval status | Investigational / off-label |
| Research papers | 4 |
Mounjaro is not FDA-approved for fertility ("ozempic babies"); the research below reflects investigational or off-label study only.
Research on tirzepatide for fertility ("ozempic babies") (4)
- The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception.
- Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program.
- Tirzepatide for fertility-sparing treatment in obese/overweight patients with endometrial cancer and atypical hyperplasia: a phase II single-arm clinical trial protocol.
- Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.